Keen Eye and Ultivue Announce Collaborative Agreement to Propel Multiplex and Spatial Analysis in Clinical Research
Keen Eye, a leading AI company in digital pathology for clinical research and Ultivue, Inc. an industry leader in multiplexing tools and novel image analysis solutions for tissue biomarker studies, announce a collaborative agreement to promote multiplexed immunofluorescence (mIF) assays and scalable AI applications to unlock spatial analysis in clinical research.
Ultivue develops unique solutions for use in mIF applications, imaging and spatial phenomics. Its proprietary InSituPlex® technology enabling improved signal to noise data is designed for fast and comprehensive exploration of biologically relevant targets, up to 12-plex, with same slide-H&E analysis in tissue samples. This technology combines the power of computational pathology & spatial biology to guide translational science in immuno-oncology.
Ultivue recognizes the need for dedicated and custom AI models to analyze the complexity of mIF data at scale and to provide improved turn-around times and consistent readouts across large cohorts “We are looking forward to accelerating data generation for biopharma customers from mIF kits by partnering with Keen Eye. We can jointly support more scalable workflows which will allow us to meet increasing demand in clinical trials.” said Florian Leiss, Ph.D. Vice President Digital Health Strategies at Ultivue.
Keen Eye is an AI Platform company dedicated to deliver accurate, standardized, and undiscovered tissue insights in research and clinical development using Deep Learning histopathology digital image analysis. Its proprietary models dedicated for spatial exploration of tumor microenvironment give access to reliable tissue segmentation, biomarker quantification, cell population profiling, and morphological discovery.
Thanks to Ultivue’s pre-optimized assays, the high accuracy achieved for every biomarker will drastically reduce errors during quantification steps as phenotypes combine several biomarkers. As Dr. Sylvain Berlemont, Keen Eye’s founder and CEO says, “We are thrilled to expand our application portfolio combined with best-in-class Ultivue mIF assays to biopharma companies and CROs. This partnership will undeniably support our customers to fully extend reproducibility and scalability throughout their clinical research.”.
About Keen Eye
Keen Eye is a health technology company based in Paris, aiming to bring AI into every research laboratory, CRO and pharmaceutical company, for the benefit of biologists, pathologists, and patients. Keen Eye is building decision-support and GCLP-compliant image analysis solutions relying on Deep Learning technology through web-based platforms. Keen Eye strives to support the development of new therapies with better, faster, and accurate analytics. Learn more at keeneye.ai.
Ultivue provides researchers and scientists in translational medicine with multiplex biomarker assays for tissue phenotyping and digital pathology. Its proprietary InSituPlex® technology enables advanced exploration and interrogation of tissue samples for precision medicine research. These highly customizable solutions coupled with our scientific consultative approach strengthen and accelerate biomarker discovery and drug development programs. Learn more at Ultivue.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Sylvain Berlemont, Ph.D
CEO and Founder
Florian Leiss Ph.D
Vice President Digital Health Strategies
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lumenis OptiLight Wins 2022 MedTech Breakthrough Award: Best New Technology Solution for Ophthalmology25.5.2022 16:23:00 EEST | Press release
Lumenis Be., a leading energy-based medical device company for aesthetic and eye care applications, today announced that OptiLight has received the highly competitive MedTech Breakthrough Award for “Best New Technology Solution for Ophthalmology.” This year, MedTech’s range of health and medical technology categories attracted more than 3,900 nominations from over 15 countries, from which MedTech selected OptiLight for this prestigious recognition. The win follows Lumenis’ MedTech awards for Best Overall Medical Device Company in 2021 and Best New Surgical Technology Solution in 2020. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220525005607/en/ (Graphic: Business Wire) OptiLight is a groundbreaking, light-based treatment. It is the first and only light treatment FDA approved for management of dry eye disease, a very common condition that causes dry, gritty eyes and fluctuating vision for an estimated 49 million Americans.
Everest Technologies Recognized by Manhattan Associates for Commerce Services25.5.2022 16:00:00 EEST | Press release
Everest Technologies today announced that it has been named as the winner of the Commerce Services Partner of the Year award by Manhattan Associates. The awards were presented at Momentum 2022, Manhattan Associates’ annual event, held on May 23-25 in Florida. At Momentum 2022, the partners were recognized for their exceptional work in providing top-quality solutions and services that address complex business challenges and continuously drive success, value and return on investment for the customers. Commenting on the award win, Eric Lamphier, Senior Director of Alliances, said, “Manhattan Associates is committed to developing, supporting, and recognizing innovations that build a smooth supply chain and improve the end consumer experience. We are conscious of the value add of our robust partner network and are proud of the innovative and efficient solutions developed by them to make our customers continue seamlessly on their business journey.” “We are very passionate and deliberate abou
Upflex Announces $30M Series A From Top Strategic & Venture Funds25.5.2022 16:00:00 EEST | Press release
Upflex—the premier global provider of hybrid workspace solutions—announced the closing of its $30 million Series A round. The raise was led by WeWork with participation from notable strategic investors Newmark and Cushman & Wakefield as well as returning investor Ecosystem Integrity Fund, and top venture funds including GPO Fund, Coelius Capital, Industry Ventures, Inertia Ventures, Perennial Private Investments, and Silicon Valley Bank. This brings Upflex’s total funds raised to-date to $34.1 million. Upflex entered into a strategic and exclusive partnership with WeWork in February 2022 which increased Upflex’s global network to over 6,000 bookable locations. As the sole aggregator of WeWork inventory, Upflex and WeWork clients now benefit from enhanced optionality in workspaces as they aim to adopt hybrid work strategies. “We’re excited and humbled to partner with global leaders in commercial real estate and top proptech investors who bring the market expertise and the financial back
Q4 Inc. and Diligent Partner to Deliver Best-In-Class Board Governance and Investor Relations Solutions to Pre-IPO and Public Companies25.5.2022 16:00:00 EEST | Press release
Q4 Inc. (TSX: QFOR) (“Q4”), a leading capital markets communications platform provider, and Diligent, a global leader in modern governance providing SaaS solutions across governance, risk, compliance and ESG, today announced a partnership that will afford pre-IPO and public companies easy access to best-of-breed IR and board governance solutions, equipping them with the tools needed to achieve success at scale. Through the partnership, listing companies will benefit from Diligent’s Board & Leadership Collaboration solution and Q4’s end-to-end Investor Relations platform in one easily accessible offering, allowing them to quickly implement market-leading solutions to fuel good governance and investor relations pre-IPO and beyond. Diligent’s end-to-end Board & Leadership Collaboration solution empowers and informs governance best practices for publicly traded companies across the fiscal year, from routine filings to preparing for an annual general meeting. Meanwhile, Q4’s Investor Relati
Machinations.io Raises $3.3M in Series A Round Led By Hiro Capital25.5.2022 16:00:00 EEST | Press release
Machinations.io, the only platform to design and predict game economies & systems for premium, free2play, and play2earn games, announced today the closing of a $3.3M Series A round, led by Hiro Capital. Machinations will invest the capital into hiring and developing powerful new features. “The team at Machinations.io has forged a set of tools that will be foundational in the future of game design, both centralised games and Web3,” said Spike Laurie, partner at Hiro Capital. “The ability for any development studio to use Machinations’ platform to create in-game economies in a streamlined browser-based solution is revolutionary. We’re excited to help the Machinations team take their vision to game creators across the globe.” Machinations.io was specifically built to tackle the difficulties of designing game economies. It enables game designers to express game systems and perform large-scale simulations to get millions of gameplay progression data with one click of a button. “We’re humble
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom